Characterization of monomeric and homodimeric forms of osteoclastogenesis inhibitory factor.

The Thiobarbituric Acid Assay of Sialic Acids

Warren, L. (1959) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)69851-5 · Cited by 6,443 · see citing works

Osteoprotegerin: a novel secreted protein involved in the regulation of bone density.

Simonet, W. S., Lacey, D. L., Dunstan, C. R., Kelley, M., Chang, M.-S., Lüthy, R., Nguyen, H. Q., Wooden, S., Bennett, L., Boone, T., et al. (1997) · Cell · doi:10.1016/s0092-8674(00)80209-3 · Cited by 5,130 · see citing works

The polypeptide encoded by the cDNA for human cell surface antigen Fas can mediate apoptosis

Itoh, N., Yonehara, S., Ishii, A., Yonehara, M., Mizushima, S.-I., Sameshima, M., Hase, A., Seto, Y., & Nagata, S. (1991) · Cell · doi:10.1016/0092-8674(91)90614-5 · Cited by 2,736 · see citing works

The Preparation and Enzymatic Hydrolysis of Reduced and S-Carboxymethylated Proteins

Crestfield, A. M., Moore, S., & Stein, W. H. (1963) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)81308-4 · Cited by 2,587 · see citing works

Cell surface, heparin-like molecules are required for binding of basic fibroblast growth factor to its high affinity receptor

Yayon, A., Klagsbrun, M., Esko, J. D., Leder, P., & Ornitz, D. M. (1991) · Cell · doi:10.1016/0092-8674(91)90512-w · Cited by 2,440 · see citing works

Principles of Bone Biology

(2019) · Elsevier eBooks · doi:10.1016/c2015-1-01622-2 · Cited by 1,690 · see citing works

Requirement of Heparan Sulfate for bFGF-Mediated Fibroblast Growth and Myoblast Differentiation

Rapraeger, A. C., Krufka, A., & Olwin, B. B. (1991) · Science · doi:10.1126/science.1646484 · Cited by 1,508 · see citing works

Principles of Bone Biology

Compston, J. E. (1997) · Clinical Endocrinology · doi:10.1046/j.1365-2265.1997.2431019.x · Cited by 1,383 · see citing works

The Vascular Endothelial Growth Factor Family: Identification of a Fourth Molecular Species and Characterization of Alternative Splicing of RNA

Houck, K. A., Ferrara, N., Winer, J., Cachianes, G., Li, B., & Leung, D. W. (1991) · Molecular Endocrinology · doi:10.1210/mend-5-12-1806 · Cited by 1,364 · see citing works

Identity of Osteoclastogenesis Inhibitory Factor (OCIF) and Osteoprotegerin (OPG): A Mechanism by which OPG/OCIF Inhibits Osteoclastogenesis<i>in Vitro</i>¹

Yasuda, H., Shima, N., Nakagawa, N., Mochizuki, S.-I., Yano, K., Fujise, N., Sato, Y., Goto, M., Yamaguchi, K., Kuriyama, M., et al. (1998) · Endocrinology · doi:10.1210/endo.139.3.5837 · Cited by 1,201 · see citing works

Molecular cloning and expression of a receptor for human tumor necrosis factor

Schall, T. J., Lewis, M., Koller, K. J., Lee, A. L., Rice, G. C., Wong, G. H., Gatanaga, T., Granger, G. A., Lentz, R., Raab, H. E., et al. (1990) · Cell · doi:10.1016/0092-8674(90)90816-w · Cited by 958 · see citing works

A Receptor for Tumor Necrosis Factor Defines an Unusual Family of Cellular and Viral Proteins

Smith, C. A., Davis, T., Anderson, D. M., Solam, L., Beckmann, M. P., Jerzy, R., Dower, S., Cosman, D. J., & Goodwin, R. G. (1990) · Science · doi:10.1126/science.2160731 · Cited by 952 · see citing works

Nonenzymatic Cleavage of Peptide Bonds: The Methionine Residues in Bovine Pancreatic Ribonuclease

Gross, E., & Witkop, B. (1962) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)73948-9 · Cited by 927 · see citing works

Isolation of a novel cytokine from human fibroblasts that specifically inhibits osteoclastogenesis.

Tsuda, E., Goto, M., Mochizuki, S.-I., Yano, K., Kobayashi, F., Morinaga, T., & Higashio, K. (1997) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1997.6603 · Cited by 787 · see citing works

Identification, purification, and biological characterization of hematopoietic stem cell factor from buffalo rat liver-conditioned medium

Zsebo, K. M., Wypych, J., McNiece, I., Lu, H. S., Smith, K. A., Karkare, S. B., Sachdev, R. K., Yuschenkoff, V. N., Birkett, N. C., Williams, L. R., et al. (1990) · Cell · doi:10.1016/0092-8674(90)90300-4 · Cited by 786 · see citing works

Disorders of Bone and Mineral Metabolism

Coe, F. L., Favus, M. J., & Davids, J. R. (1992) · Journal of Pediatric Orthopaedics · doi:10.1097/01241398-199211000-00022 · Cited by 734 · see citing works

Extracellular Ca2+ sensing, regulation of parathyroid cell function, and role of Ca2+ and other ions as extracellular (first) messengers

Brown, E. M. (1991) · Physiological Reviews · doi:10.1152/physrev.1991.71.2.371 · Cited by 696 · see citing works

Heparin Is Required for Cell-Free Binding of Basic Fibroblast Growth Factor to a Soluble Receptor and for Mitogenesis in Whole Cells

Ornitz, D. M., Yayon, A., Flanagan, J. G., Svahn, C. M., Levi, E., & Leder, P. (1992) · Molecular and Cellular Biology · doi:10.1128/mcb.12.1.240 · Cited by 632 · see citing works

An Essential Heparin-Binding Domain in the Fibroblast Growth Factor Receptor Kinase

Kan, M., Wang, F., Xu, J., Crabb, J. W., Hou, J., & McKeehan, W. L. (1993) · Science · doi:10.1126/science.8456318 · Cited by 516 · see citing works

A B‐lymphocyte activation molecule related to the nerve growth factor receptor and induced by cytokines in carcinomas.

Stamenkovic, I., Clark, E. A., & Seed, B. (1989) · The EMBO Journal · doi:10.1002/j.1460-2075.1989.tb03521.x · Cited by 512 · see citing works

The binding of vascular endothelial growth factor to its receptors is dependent on cell surface-associated heparin-like molecules.

Gitay-Goren, H., Söker, S., Vlodavsky, I., & Neufeld, G. (1992) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)42666-x · Cited by 490 · see citing works

A new method for determining micro quantities of calcium in biological materials

Sarkar, B., & Chauhan, U. P. S. (1967) · Analytical Biochemistry · doi:10.1016/0003-2697(67)90273-4 · Cited by 352 · see citing works

Natural human interferon-gamma. Complete amino acid sequence and determination of sites of glycosylation.

Rinderknecht, E., O'Connor, B. H., & Rodriguez, H. (1984) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)39797-1 · Cited by 271 · see citing works

Structural characterization of natural human urinary and recombinant DNA-derived erythropoietin. Identification of des-arginine 166 erythropoietin.

Recny, M. A., Scoble, H. A., & Kim, Y. (1987) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)45504-4 · Cited by 209 · see citing works

Characterization of Structural Domains of Human Osteoclastogenesis Inhibitory Factor

Yamaguchi, K., Kinosaki, M., Goto, M., Kobayashi, F., Tsuda, E., Morinaga, T., & Higashio, K. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.9.5117 · Cited by 200 · see citing works

Compartmentalization of PDGF on extracellular binding sites dependent on exon-6-encoded sequences.

Raines, E. W., & Ross, R. (1992) · The Journal of Cell Biology · doi:10.1083/jcb.116.2.533 · Cited by 177 · see citing works

Heparin induces dimerization and confers proliferative activity onto the hepatocyte growth factor antagonists NK1 and NK2.

SCHWALL, R. H., Chang, L. Y., Godowski, P. J., Kahn, D. W., Hillan, K. J., Bauer, K. D., & Zioncheck, T. F. (1996) · The Journal of Cell Biology · doi:10.1083/jcb.133.3.709 · Cited by 140 · see citing works

Identification of a cell retention signal in the B-chain of platelet-derived growth factor and in the long splice version of the A-chain.

Östman, A., Andersson, M. A., Betsholtz, C., Westermark, B., & Heldin, C. (1991) · Cell Regulation · doi:10.1091/mbc.2.7.503 · Cited by 137 · see citing works

Identification of heparan sulfate proteoglycan as a high affinity receptor for acidic fibroblast growth factor (aFGF) in a parathyroid cell line.

Sakaguchi, K., Yanagishita, M., Takeuchi, Y., & Aurbach, G. D. (1991) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(20)89640-9 · Cited by 86 · see citing works

Heparin Modulates the Receptor-Binding and Mitogenic Activity of Hepatocyte Growth Factor on Hepatocytes

Naka, D., Ishii, T., Shimomura, T., HISHIDA, T., & Hara, H. (1993) · Experimental Cell Research · doi:10.1006/excr.1993.1316 · Cited by 68 · see citing works

Disorders of Bone and Mineral Metabolism

Wallis, L. A. (1993) · JAMA · doi:10.1001/jama.1993.03500100113044 · Cited by 64 · see citing works

Cellular and Molecular Mechanisms in the Regulation and Function of Osteoclasts

Chambers, T. J., & Hall, T. J. (1991) · Vitamins and hormones · doi:10.1016/s0083-6729(08)60682-2 · Cited by 57 · see citing works

Identification of the N-terminal residue of the heavy chain of both native and recombinant human hepatocyte growth factor

Yoshiyama, Y., Arakaki, N., Naka, D., Takahashi, K., Hirono, S., Kondo, J., Nakayama, H., Gohda, E., Kitamura, N., Tsubouchi, H., et al. (1991) · Biochemical and Biophysical Research Communications · doi:10.1016/0006-291x(91)91616-k · Cited by 56 · see citing works

Modulation of Osteoclast Differentiation and Function by the New Members of the Tumor Necrosis Factor Receptor and Ligand Families

Suda, T., Takahashi, N., Udagawa, N., Jimi, E., Gillespie, M. T., & Martin, T. J. (1999) · Endocrine Reviews · doi:10.1210/edrv.20.3.0367 · Cited by 2,317 · see citing works

The Roles of Osteoprotegerin and Osteoprotegerin Ligand in the Paracrine Regulation of Bone Resorption

Hofbauer, L. C., Khosla, S., Dunstan, C. R., Lacey, D. L., Boyle, W. J., & Riggs, B. L. (2000) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.2000.15.1.2 · Cited by 1,167 · see citing works

Receptor Activator of Nuclear Factor κB Ligand and Osteoprotegerin Regulation of Bone Remodeling in Health and Disease

Kearns, A. E., Khosla, S., & Kostenuik, P. J. (2008) · Endocrine Reviews · doi:10.1210/er.2007-0014 · Cited by 824 · see citing works

RANK Is the Essential Signaling Receptor for Osteoclast Differentiation Factor in Osteoclastogenesis

Nakagawa, N., Kinosaki, M., Yamaguchi, K., Shima, N., Yasuda, H., Yano, K., Morinaga, T., & Higashio, K. (1998) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1998.9788 · Cited by 746 · see citing works

Bench to bedside: elucidation of the OPG–RANK–RANKL pathway and the development of denosumab

Lacey, D. L., Boyle, W. J., Simonet, W. S., Kostenuik, P. J., Dougall, W. C., Sullivan, J. K., Martín, J. S., & Dansey, R. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd3705 · Cited by 692 · see citing works

Role of receptor activator of nuclear factor-κB ligand and osteoprotegerin in bone cell biology

Hofbauer, L. C., & Heufelder, A. E. (2001) · Journal of Molecular Medicine · doi:10.1007/s001090100226 · Cited by 586 · see citing works

Parathyroid hormone stimulates TRANCE and inhibits osteoprotegerin messenger ribonucleic acid expression in murine bone marrow cultures: correlation with osteoclast-like cell formation.

Lee, S.-K., & Lorenzo, J. A. (1999) · Endocrinology · doi:10.1210/endo.140.8.6887 · Cited by 464 · see citing works

A New Member of Tumor Necrosis Factor Ligand Family, ODF/OPGL/TRANCE/RANKL, Regulates Osteoclast Differentiation and Function

Takahashi, N., Udagawa, N., & Suda, T. (1999) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1999.0252 · Cited by 461 · see citing works

Osteoblasts/stromal cells stimulate osteoclast activation through expression of osteoclast differentiation factor/RANKL but not macrophage colony-stimulating factor

Udagawa, N., Takahashi, N., Jimi, E., Matsuzaki, K., Tsurukai, T., Itoh, K., Nakagawa, N., Yasuda, H., Goto, M., Tsuda, E., et al. (1999) · Bone · doi:10.1016/s8756-3282(99)00210-0 · Cited by 410 · see citing works

RANK Ligand and Osteoprotegerin

Schoppet, M., Preissner, K. T., & Hofbauer, L. C. (2002) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/01.atv.0000012303.37971.da · Cited by 403 · see citing works

Osteoprotegerin Produced by Osteoblasts Is an Important Regulator in Osteoclast Development and Function

Udagawa, N., Takahashi, N., Yasuda, H., Mizuno, A., Itoh, K., Ueno, Y., Shinki, T., Gillespie, M. T., Martin, T. J., Higashio, K., et al. (2000) · Endocrinology · doi:10.1210/endo.141.9.7634 · Cited by 403 · see citing works

Immunological characterization of circulating osteoprotegerin/osteoclastogenesis inhibitory factor: increased serum concentrations in postmenopausal women with osteoporosis.

Yano, K., Tsuda, E., Washida, N., Kobayashi, F., Goto, M., Harada, A., Ikeda, K., Higashio, K., & Yamada, Y. (1999) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.1999.14.4.518 · Cited by 363 · see citing works

A novel molecular mechanism modulating osteoclast differentiation and function

Yasuda, H., Shima, N., Nakagawa, N., Yamaguchi, K., Kinosaki, M., Goto, M., Mochizuki, S.-I., Tsuda, E., Morinaga, T., Udagawa, N., et al. (1999) · Bone · doi:10.1016/s8756-3282(99)00121-0 · Cited by 262 · see citing works

TRANCE is a TNF family member that regulates dendritic cell and osteoclast function

Wong, B. R., Josien, R., & Choi, Y. (1999) · Journal of Leukocyte Biology · doi:10.1002/jlb.65.6.715 · Cited by 230 · see citing works

Correlates of osteoprotegerin levels in women and men.

Khosla, S., Arrighi, H. M., Melton, III, Atkinson, E. J., O'Fallon, W. M., Dunstan, C., & Riggs, B. L. (2002) · Osteoporosis International · doi:10.1007/s001980200045 · Cited by 205 · see citing works

Increased frequency ofATM mutations in breast carcinoma patients with early onset disease and positive family history

Teraoka, S. N., Malone, K. E., Doody, D. R., Suter, N. M., Ostrander, E. A., Daling, J. R., & CONCANNON, P. J. (2001) · Cancer · doi:10.1002/1097-0142(20010801)92:3 · Cited by 111 · see citing works

The Role of Receptor Activator of Nuclear Factor- B Ligand and Osteoprotegerin in the Pathogenesis and Treatment of Metabolic Bone Diseases

Hofbauer, L. C., & Heufelder, A. E. (2000) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.85.7.6702 · Cited by 175 · see citing works

Structural and Functional Insights of RANKL–RANK Interaction and Signaling

Liu, C., Walter, T. S., Huang, P., Zhang, S., Zhu, X., Wu, Y., Wedderburn, L. R., Tang, P., Owens, R. J., Stuart, D. I., et al. (2010) · The Journal of Immunology · doi:10.4049/jimmunol.0904033 · Cited by 138 · see citing works

Investigating the Interaction between Osteoprotegerin and Receptor Activator of NF-κB or Tumor Necrosis Factor-related Apoptosis-inducing Ligand

Vitovski, S., Phillips, J. S., Sayers, J. R., & Croucher, P. I. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m706078200 · Cited by 133 · see citing works

Osteoprotegerin ligand and osteoprotegerin: novel implications for osteoclast biology and bone metabolism

Hofbauer, L. C. (1999) · European Journal of Endocrinology · doi:10.1530/eje.0.1410195 · Cited by 120 · see citing works

Functional Dissection of Osteoprotegerin and Its Interaction with Receptor Activator of NF-κB Ligand

Schneeweis, L. A., Willard, D., & Milla, M. E. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m506366200 · Cited by 116 · see citing works

Osteoclast formation and resorption

Lerner, U. H. (2000) · Matrix Biology · doi:10.1016/s0945-053x(00)00052-4 · Cited by 114 · see citing works

Osteoclastogenesis inhibitory factor (OCIF) directly inhibits bone-resorbing activity of isolated mature osteoclasts.

Hakeda, Y., Kobayashi, Y., Yamaguchi, K., Yasuda, H., Tsuda, E., Higashio, K., Miyata, T., & Kumegawa, M. (1998) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1998.9523 · Cited by 107 · see citing works

High levels of soluble syndecan-1 in myeloma-derived bone marrow: modulation of hepatocyte growth factor activity

Seidel, C., Børset, M., Hjertner, Ø., Cao, D., Abildgaard, N., Hjorth‐Hansen, H., Sanderson, R. D., Waage, A., & Sundan, A. (2000) · Blood · doi:10.1182/blood.v96.9.3139 · Cited by 106 · see citing works

RANKL/OPG/TRAIL plasma levels and bone mass loss evaluation in antiretroviral naive HIV‐1‐positive men

Gibellini, D., Borderi, M., Crignis, E. D., Cicola, R., Vescini, F., Caudarella, R., Chiodo, F., & Re, M. C. (2007) · Journal of Medical Virology · doi:10.1002/jmv.20938 · Cited by 102 · see citing works

Osteoprotegerin (OPG) acts as an endogenous decoy receptor in tumour necrosis factor-related apoptosis-inducing ligand (TRAIL)-mediated apoptosis of fibroblast-like synovial cells

Miyashita, T., Kawakami, A., Nakashima, T., Yamasaki, S., Tamai, M., Tanaka, F., Kamachi, M., Ida, H., Migita, K., Origuchi, T., et al. (2004) · Clinical & Experimental Immunology · doi:10.1111/j.1365-2249.2004.02534.x · Cited by 74 · see citing works

Plasma osteoprotegerin levels predict cardiovascular and all-cause mortality and deterioration of kidney function in type 1 diabetic patients with nephropathy

Jorsal, A., Tarnow, L., Flyvbjerg, A., Parving, H.-H., Rossing, P. R., & Rasmussen, L. M. (2008) · Diabetologia · doi:10.1007/s00125-008-1123-8 · Cited by 71 · see citing works

Osteoprotegerin, an endogenous antiosteoclast factor for protecting bone in rheumatoid arthritis

Bolon, B. N., Shalhoub, V., Kostenuik, P. J., Campagnuolo, G., Morony, S., Boyle, W. J., Zack, D. J., & Feige, U. (2002) · Arthritis & Rheumatism · doi:10.1002/art.10680 · Cited by 57 · see citing works

Mechanisms of bone loss in rheumatoid arthritis

Findlay, D. M., & Haynes, D. R. (2005) · Modern Rheumatology · doi:10.1007/s10165-005-0412-z · Cited by 55 · see citing works

The Roadmap of RANKL/RANK Pathway in Cancer

Casimiro, S., Vilhais, G., Gomes, I., & Costa, L. (2021) · Cells · doi:10.3390/cells10081978 · Cited by 54 · see citing works

TRAIL and osteoprotegerin: a role in endothelial physiopathology?

Corallini, F. (2007) · Frontiers in bioscience · doi:10.2741/2665 · Cited by 50 · see citing works

Osteoprotegerin in Human Milk: A Potential Role in the Regulation of Bone Metabolism and Immune Development

Vidal, K., BROEK, P. V. D., Lorget, F., & Donnet‐Hughes, A. (2004) · Pediatric Research · doi:10.1203/01.pdr.0000127014.22068.15 · Cited by 46 · see citing works

Osteoprotegerin production by human intestinal epithelial cells: a potential regulator of mucosal immune responses

Vidal, K., Serrant, P., Schlosser, B., BROEK, P. V. D., Lorget, F., & Donnet‐Hughes, A. (2004) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00428.2003 · Cited by 44 · see citing works

Juvenile Paget's Disease: The Second Reported, Oldest Patient Is Homozygous for the TNFRSF11B “Balkan” Mutation (966_969delTGACinsCTT), Which Elevates Circulating Immunoreactive Osteoprotegerin Levels

Whyte, M. P., Singhellakis, P. N., Petersen, M. B., Davies, M., Totty, W. G., & Mumm, S. R. (2007) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.070307 · Cited by 42 · see citing works

Osteoprotegerin and Osteoprotegerin-Ligand Balance: a New Paradigm in Bone Metabolism Providing New Therapeutic Targets

Lories, R. J. U., & Luyten, F. P. (2001) · Clinical Rheumatology · doi:10.1007/s100670170095 · Cited by 43 · see citing works

One Year of Transgenic Overexpression of Osteoprotegerin in Rats Suppressed Bone Resorption and Increased Vertebral Bone Volume, Density, and Strength

Ominsky, M. S., Stolina, M., Li, X., Corbin, T. J., Asuncion, F., Barrero, M., Niu, Q., Dwyer, D., Adamu, S., Warmington, K. S., et al. (2009) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.090215 · Cited by 42 · see citing works

An intermediate form of juvenile Paget’s disease caused by a truncating TNFRSF11B mutation.

Janssens, K., de Vernejoul, M.-C., de Freitas, F., Vanhoenacker, F., & Van Hul, W. (2005) · Bone · doi:10.1016/j.bone.2004.12.004 · Cited by 40 · see citing works

Vitamin D and Osteoclastogenesis

Yasuda, H., Higashio, K., & Suda, T. (2005) · Elsevier eBooks · doi:10.1016/b978-012252687-9/50041-3 · Cited by 34 · see citing works

Application of immuno-PCR for the detection of early stage cancer

Khan, A. H., & Sadroddiny, E. (2016) · Molecular and Cellular Probes · doi:10.1016/j.mcp.2016.01.010 · Cited by 32 · see citing works

ELISA Methodology for Detection of Modified Osteoprotegerin in Clinical Studies

Chen, D., Sarikaya, N., Gunn, H., Martin, S. W., & Young, J. D. (2001) · Clinical Chemistry · doi:10.1093/clinchem/47.4.747 · Cited by 32 · see citing works

Comparison of the effects of 17β-E2 and progesterone on the expression of osteoprotegerin in normal human osteoblast-like cells

Liao, E. Y., Luo, X., & Su, X. (2002) · Journal of Endocrinological Investigation · doi:10.1007/bf03345513 · Cited by 32 · see citing works

Murine osteoclasts secrete serine protease HtrA1 capable of degrading osteoprotegerin in the bone microenvironment

Ochiai, N., Nakachi, Y., Yokoo, T., Ichihara, T., Eriksson, T., Yonemoto, Y., Kato, T., Ogata, H., Fujimoto, N., Kobayashi, Y., et al. (2019) · Communications Biology · doi:10.1038/s42003-019-0334-5 · Cited by 25 · see citing works

Osteoclastogenesis inhibitory factor/osteoprotegerin ameliorates the decrease in both bone mineral density and bone strength in immobilized rats.

Mochizuki, S.-I., Fujise, N., Higashio, K., & Tsuda, E. (2002) · Journal of Bone and Mineral Metabolism · doi:10.1007/s774-002-8441-x · Cited by 24 · see citing works

Variations along the 24-hour cycle of circulating osteoprotegerin and soluble RANKL: a rhythmometric analysis

Dovio, A., Generali, D., Tampellini, M., Berruti, A., Tedoldi, S., TORTA, M., Bonardi, S., Tucci, M., Allevi, G., Aguggini, S., et al. (2007) · Osteoporosis International · doi:10.1007/s00198-007-0423-z · Cited by 24 · see citing works

Osteoprotegerin is present on the membrane of osteoclasts isolated from mouse long bones

Woo, K. M., Choi, Y., Ko, S., Ko, J. S., Oh, K., & Kim, K.-K. (2002) · Experimental & Molecular Medicine · doi:10.1038/emm.2002.49 · Cited by 23 · see citing works

Osteoprotegerin and bone mineral metabolism in renal failure

Kazama, J. J. (2004) · Current Opinion in Nephrology & Hypertension · doi:10.1097/01.mnh.0000133982.40182.8a · Cited by 23 · see citing works

Native osteoprotegerin gene transfer inhibits the development of murine osteolytic bone disease induced by tumor xenografts.

Doran, P. M., Turner, R. T., Chen, D., Facteau, S. M., Ludvigson, J. M., Khosla, S., Riggs, B. L., & Russell, S. J. (2004) · Experimental Hematology · doi:10.1016/j.exphem.2004.01.006 · Cited by 22 · see citing works

Nitidine chloride prevents OVX-induced bone loss via suppressing NFATc1-mediated osteoclast differentiation

Liu, Q., Wang, T., Zhou, L., Song, F., Qin, A., Feng, H., Lin, X. X., Lin, Z., Yuan, J., Tickner, J. C., et al. (2016) · Scientific Reports · doi:10.1038/srep36662 · Cited by 22 · see citing works

Cumambrin A prevents OVX‐induced osteoporosis via the inhibition of osteoclastogenesis, bone resorption, and RANKL signaling pathways

Zhou, L., Liu, Q., Hong, G., Song, F., Zhao, J., Yuan, J., Xu, J., Tan, R. X., Tickner, J. C., Gu, Q., et al. (2019) · The FASEB Journal · doi:10.1096/fj.201800883rrr · Cited by 18 · see citing works

Development of the Skeleton

Provot, S., Schipani, E., Wu, J. Y., & Kronenberg, H. M. (2013) · Elsevier eBooks · doi:10.1016/b978-0-12-415853-5.00006-6 · Cited by 17 · see citing works

Variations in Circulating Osteoprotegerin and Soluble RANKL during Diurnal and Menstrual Cycles in Young Women

Shimizu, M., Onoe, Y., 三雲, 美., Miyabara, Y., Kuroda, T., Yoshikata, R., Ishitani, K., Okano, H., & Ohta, H. (2009) · Hormone Research in Paediatrics · doi:10.1159/000208802 · Cited by 17 · see citing works

Immuno-PCR Assay for Homodimeric Osteoprotegerin

Furuya, D., Kaneko, R., Yagihashi, A., Endoh, T., Yajima, T., Kobayashi, D., Yano, K., Tsuda, E., & Watanabe, N. (2001) · Clinical Chemistry · doi:10.1093/clinchem/47.8.1475 · Cited by 16 · see citing works

Osteoprotegerin (OPG) pathways in bone diseases and its application in therapeutic perspectives

Jayash, S. N., Al-Namnam, N. M., & Shaghayegh, G. (2020) · Biointerface Research in Applied Chemistry · doi:10.33263/briac102.193200 · Cited by 15 · see citing works

The role of osteoprotegerin (OPG) receptor activator for nuclear factor kappaB ligand (RANKL) in cardiovascular pathology – a review

Malliga, D.-E., Wagner, D., & Fahrleitner‐Pammer, A. (2011) · Wiener Medizinische Wochenschrift · doi:10.1007/s10354-011-0022-7 · Cited by 13 · see citing works

On the Evolution and Contemporary Roles of Bone Remodeling

Kostenuik, P. J. (2013) · Elsevier eBooks · doi:10.1016/b978-0-12-415853-5.00037-6 · Cited by 11 · see citing works

Novel approaches to the management of bone metastases

Hortobágyi, G. N. (2003) · Seminars in Oncology · doi:10.1053/j.seminoncol.2003.08.018 · Cited by 11 · see citing works

The pathogenesis of osteoclast diseases: Some knowns, but still many unknowns

Helfrich, M., Crockett, J. C., Hocking, L. J., & Coxon, F. P. (2007) · BoneKEy-Osteovision · doi:10.1138/20060249 · Cited by 9 · see citing works

Circulating osteoprotegerin in women during GnRH-agonist treatment and their relationships with mineral components and biomarkers of bone turnover

Uemura, H., Yasui, T., Umino, Y., Niki, H., Takikawa, M., Saito, S., Furumoto, H., & Irahara, M. (2003) · Bone · doi:10.1016/j.bone.2003.08.001 · Cited by 7 · see citing works

Osteoprotegerin: regulator, protector and marker

Othmane, T., Speer, G., Fekete, B., Szabó, T., Egresits, J., Fodor, E., Kiss, I., Nemcsik, J., Szabó, A., Németh, Z., et al. (2008) · Orvosi Hetilap · doi:10.1556/oh.2008.28470 · Cited by 7 · see citing works

Rank-Rankl-Opg Axis in Multiple Sclerosis: The Contribution of Placenta

Passaponti, S., Ermini, L., Acconci, G., Severi, F. M., Romagnoli, R., Cutrupi, S., Clerico, M., Guerrera, G., & Ietta, F. (2022) · Cells · doi:10.3390/cells11081357 · Cited by 7 · see citing works

PEGylation of osteoprotegerin/osteoclastogenesis inhibitory factor (OPG/OCIF) results in decreased uptake into rats and human liver

Saito-Yabe, M., Kasuya, Y., Yoshigae, Y., Yamamura, N., Suzuki, Y., Fukuda, N., Honma, M., Yano, K., Mochizuki, S.-I., Okada, F., et al. (2010) · Journal of Pharmacy and Pharmacology · doi:10.1111/j.2042-7158.2010.01120.x · Cited by 7 · see citing works

Pharmacokinetics and disposition of recombinant human osteoprotegerin (rhOPG) after intravenous administration in female fischer rats

Miyaji, Y., Kurihara, A., Kamiyama, E., Shiiki, T., Kawai, K., & Okazaki, O. (2009) · Xenobiotica · doi:10.1080/00498250802590745 · Cited by 7 · see citing works

Osteoporosis induced by cellular senescence: A mathematical model

Siewe, N., & Friedman, A. (2024) · PLoS ONE · doi:10.1371/journal.pone.0303978 · Cited by 5 · see citing works

Novel Comb-Shaped PEG Modification Enhances the Osteoclastic Inhibitory Effect and Bone Delivery of Osteoprotegerin After Intravenous Administration in Ovariectomized Rats

Miyaji, Y., Kasuya, Y., Furuta, Y., Kurihara, A., Takahashi, M., Ogawara, K., Izumi, T., Okazaki, O., & Higaki, K. (2012) · Pharmaceutical Research · doi:10.1007/s11095-012-0807-4 · Cited by 5 · see citing works

Breast Cancer Exosomal microRNAs Facilitate Pre-Metastatic Niche Formation in the Bone: A Mathematical Model

Siewe, N., & Friedman, A. (2023) · Bulletin of Mathematical Biology · doi:10.1007/s11538-022-01117-0 · Cited by 5 · see citing works

Laboratory Assessment of Postmenopausal Osteoporosis

Garnero, P., & Delmas, P. D. (2006) · Elsevier eBooks · doi:10.1016/b9-78-012088-5/62650-0388 · Cited by 4 · see citing works

Development of the Skeleton

Provot, S., Schipani, E., Wu, J. Y., & Kronenberg, H. M. (2008) · Elsevier eBooks · doi:10.1016/b978-012370544-0.50012-4 · Cited by 4 · see citing works

RANKL (Receptor activator of NFκB ligand)

Blake, S., & JAMES, I. (2003) · Elsevier eBooks · doi:10.1016/b978-012689663-3/50041-7 · Cited by 4 · see citing works

On the evolution and contemporary roles of bone remodeling

Kostenuik, P. J. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-813073-5.00031-9 · Cited by 2 · see citing works

Antibodies to receptor activator of nuclear factor-κ B ligand (RANKL)

Terpos, E., Christoulas, D., & Dimopoulos, M. A. (2008) · Expert Opinion on Therapeutic Patents · doi:10.1517/13543776.18.11.1265 · Cited by 2 · see citing works

Development of the skeleton

Provot, S., Schipani, E., Wu, J. Y., & Kronenberg, H. M. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-813073-5.00003-4 · Cited by 1 · see citing works

RANK and RANKL of Bones, T Cells, and the Mammary Glands

Sigl, V., & Penninger, J. M. (2015) · Elsevier eBooks · doi:10.1016/b978-0-12-800571-2.00008-6 · Cited by 1 · see citing works

Osteolyse beim Multiplen Myelom : Untersuchungen am Zellmodell

Bergmann, M., & Lorenzen, J. (2005) · RWTH Publications (RWTH Aachen)

Receptor activator of nuclear factor кB ligand (RANKL) versus osteoprotegerin (OPG): the yin and yang of joint integrity

Bolon, B. N., Shalhoub, V., Kostenuik, P. J., Zack, D. J., & Feige, U. (2004) · Birkhäuser Basel eBooks · doi:10.1007/978-3-0348-7883-8_10

Bedeutung von RANK-Ligand und Osteoprotegerin für den Knochenstoffwechsel

Hofbauer, L. C., & Schoppet, M. (2006) · Springer eBooks · doi:10.1007/3-540-28782-5_21

Osteoprotegerin: a pathological role in human abdominal aortic aneurysm

Moran, C. S. (2025) · ResearchOnline at James Cook University (James Cook University) · doi:10.25903/j9h2-9r90

Muscular Strength Training Modifies Regulation of Bone Remodeling: Inferences from Serum Biomarkers in Young Women

Mardock, M. A. (2003) · VTechWorks (Virginia Tech)

Mecanismos de calcificación vascular asociados a la uremia y al tratamiento con Calcitriol.

García, S. (2009) · TDX (Tesis Doctorals en Xarxa)

New Approaches to Osteoporosis Therapeutics

Stoch, S. A., Chorev, M., & Rosenblatt, M. (2001) · Elsevier eBooks · doi:10.1016/b978-012470862-4/50080-5

Development of the Skeleton

Provot, S., Schipani, E., Wu, J. Y., & Kronenberg, H. M. (2010) · Elsevier eBooks · doi:10.1016/b978-0-12-375098-3.50011-1

Translational Pharmacology in The Development of RANKL Inhibitors

Boyce, B. F., & Yao, Z. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-801238-3.62262-6

Role of receptor activator of NF-kB ligand (RANKL) in adult lymph node homeostasis and identification of inhibitors

Chypre, M. (2017) · doi:10.70675/c03de234z42e1z4922za9f7zd9b379be40ac

Disease-associated TNFRSF11B variants differentially disrupt osteoprotegerin secretion and function

Suzuki, R., Nishida‐Fukuda, H., Fukuda, S., Shibata, Y., Sato, T., Miyazawa, K., & Suzuki, T. (2026) · Bone · doi:10.1016/j.bone.2026.118046

Characterization of Structural Domains of Human Osteoclastogenesis Inhibitory Factor

Yamaguchi, K., Kinosaki, M., Goto, M., Kobayashi, F., Tsuda, E., Morinaga, T., & Higashio, K. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.9.5117 · Cited by 200 · see citing works

Isolation of a novel cytokine from human fibroblasts that specifically inhibits osteoclastogenesis.

Tsuda, E., Goto, M., Mochizuki, S.-I., Yano, K., Kobayashi, F., Morinaga, T., & Higashio, K. (1997) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1997.6603 · Cited by 787 · see citing works

Osteoclastogenesis inhibitory factor (OCIF) directly inhibits bone-resorbing activity of isolated mature osteoclasts.

Hakeda, Y., Kobayashi, Y., Yamaguchi, K., Yasuda, H., Tsuda, E., Higashio, K., Miyata, T., & Kumegawa, M. (1998) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1998.9523 · Cited by 107 · see citing works

Isolation and characterization of a novel cytokine termed osteoclastogenesis inhibitory factor, OCIF

望月, 伸. (2003)

In vitro and in vivo model systems used to assess bone-active factors

Cornish, J. (2000) · Bone · doi:10.1016/s8756-3282(00)80008-3